Aimovig™ (erenumab-aooe) and the prevention of migraine

Migraine is more than just a headache. It is a distinct neurological disease that changes brain biology and function.¹ ² The Global Burden of Disease Study ranks migraine among the top 10 causes of years lived with disability worldwide.³

About Migraine

People with migraine endure pain and physical impairment.⁴

More than 90% of people report impaired ability to function during migraine attacks.⁵

Approximately $11B in indirect costs is estimated to be lost by American employers each year due to migraine.⁶

People with migraine lose a substantial part of their days managing around the disease.⁷

Migraine affects not only the people living with migraine, but can also impact their families due to missed activities.⁸

Migraine is highest in those age 30 to 39 years among both men (7.4%) and women (24.4%).⁹

21% of people experience 4 or more headache days per month.⁹

Preventive medications may be an option for approximately 10 million Americans with migraine.⁷ Approximately one-third of patients who are appropriate for preventive treatment are currently or coincidentally on a preventive therapy.⁸ Now there is a new option indicated for the preventive treatment of migraine in adults: Aimovig™

- Aimovig™ is the first FDA-approved treatment specifically designed to help prevent migraine by blocking the calcitonin gene-related peptide (CGRP) receptor, which is associated with migraine pathophysiology.
- CGRP is believed to play a critical role in migraine.⁹ Levels of CGRP in the body increase at the onset of migraine and decrease following relief of migraine pain.⁹ ¹⁰
- Aimovig™ is self-administered monthly via Amgen’s SureClick® autoinjector, a single-use prefilled autoinjector.¹¹
- Aimovig™ has been studied in several randomized, double-blind, placebo-controlled studies to assess its safety and efficacy in migraine prevention. More than 3,000 patients have participated in the Aimovig™ clinical program across four placebo-controlled Phase 2 and Phase 3 clinical studies and their open-label extensions.
- In clinical trials, Aimovig™ resulted in significant reductions in monthly acute migraine-specific medication days versus placebo.¹²

Important Safety Information

The most common adverse reactions in clinical studies (≥ 3% of Aimovig™-treated patients and more often than placebo) were injection site reactions and constipation.¹¹

Find the full Prescribing Information here.
Forward-Looking Statements

This fact sheet contains forward-looking statements that are based on the current expectations and beliefs of each of Amgen and Novartis. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including expected clinical results, statements regarding the potential approval of new products and other such results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by each of Amgen and Novartis, including Amgen’s most recent annual report on Form 10K and any subsequent periodic reports on Form 10Q and Form B-K, and Novartis’ most recent annual report on Form 20F. Unless otherwise noted, Amgen and Novartis are each providing this information as of November 15, 2017 and expressly disclaim any obligation to update any forward-looking statements contained in this fact sheet as a result of new information, future events or otherwise.

No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, preclinical results do not guarantee safe and effective performance of product candidates in humans. The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models. The length of time that it takes for us to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and Amgen and Novartis each expect similar variability in the future. Even when clinical trials are successful, regulatory authorities may question the sufficiency for approval of the trial endpoints we have selected. Amgen and Novartis each develop product candidates internally and through licensing collaborations, partnerships and joint ventures. Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as believed at the time of entering into such relationship. Also, Amgen, Novartis or others could identify safety, side effects or manufacturing problems with products, including devices, of Amgen or of Novartis after they are on the market.

The results of each of Amgen and Novartis may be affected by the ability of each of Amgen and Novartis to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing its products and global economic conditions, including the effects of the persistently weak economic and financial environment in many countries. In addition, sales of our products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments, the particular prescribing preferences of physicians and patients and domestic and international trends toward managed care and healthcare cost containment. Furthermore, the research, testing, pricing, marketing and other operations of each of Amgen and Novartis are subject to extensive regulation by domestic and foreign government regulatory authorities. The business of each of Amgen and Novartis may be impacted by government investigations, litigation and product liability claims. In addition, the business of each of Amgen and Novartis may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If Amgen fails to meet the compliance obligations in the corporate integrity agreement between Amgen and the U.S. government, Amgen could become subject to significant sanctions. Further, while each of Amgen and Novartis routinely obtain patents for the products and technology of Amgen and Novartis, respectively, the protection offered by these patents and patent applications may be challenged, invalidated or circumvented by competitors of Amgen and Novartis, respectively, or each of Amgen and Novartis may fail to prevail in present and future intellectual property litigation. Amgen performs a substantial amount of its commercial manufacturing activities at a few key facilities, including in Puerto Rico, and each of Amgen and Novartis also depend on third parties for a portion of its respective manufacturing activities, and limits on supply may constrain sales of certain current products and product candidate development of each of Amgen and Novartis. In addition, each of Amgen and Novartis compete with other companies with respect to many of their respective marketed products as well as for the discovery and development of new products. Further, some raw materials, medical devices and component parts for products of each of Amgen and Novartis are supplied by sole third-party suppliers. The discovery of significant problems with materials, medical devices and component parts for products of each of Amgen and Novartis could result in delays in product development or manufacturing delays that could delay or prevent product development and marketing of both new and existing products. Furthermore, Amgen and Novartis may fail to obtain, maintain or enforce the patent protection necessary to commercialize products or product candidates developed by them or to competing products. If any of Amgen’s or Novartis’ patents or other intellectual property rights are infringed or misappropriated, or if they are found to be invalid or unenforceable, Amgen or Novartis could lose valuable rights relating to their products. The breadth of issued or allowed patents and the scope of their valid claims are uncertain and subject to challenge by third parties.

The results of each of Amgen and Novartis may be affected by the ability of each of Amgen and Novartis to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing its products and global economic conditions, including the effects of the persistently weak economic and financial environment in many countries. In addition, sales of our products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments, the particular prescribing preferences of physicians and patients and domestic and international trends toward managed care and healthcare cost containment. Furthermore, the research, testing, pricing, marketing and other operations of each of Amgen and Novartis are subject to extensive regulation by domestic and foreign government regulatory authorities. The business of each of Amgen and Novartis may be impacted by government investigations, litigation and product liability claims. In addition, the business of each of Amgen and Novartis may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If Amgen fails to meet the compliance obligations in the corporate integrity agreement between Amgen and the U.S. government, Amgen could become subject to significant sanctions. Further, while each of Amgen and Novartis routinely obtain patents for the products and technology of Amgen and Novartis, respectively, the protection offered by these patents and patent applications may be challenged, invalidated or circumvented by competitors of Amgen and Novartis, respectively, or each of Amgen and Novartis may fail to prevail in present and future intellectual property litigation. Amgen performs a substantial amount of its commercial manufacturing activities at a few key facilities, including in Puerto Rico, and each of Amgen and Novartis also depend on third parties for a portion of its respective manufacturing activities, and limits on supply may constrain sales of certain current products and product candidate development of each of Amgen and Novartis. In addition, each of Amgen and Novartis compete with other companies with respect to many of their respective marketed products as well as for the discovery and development of new products. Further, some raw materials, medical devices and component parts for products of each of Amgen and Novartis are supplied by sole third-party suppliers. The discovery of significant problems with materials, medical devices and component parts for products of each of Amgen and Novartis could result in delays in product development or manufacturing delays that could delay or prevent product development and marketing of both new and existing products. Furthermore, Amgen and Novartis may fail to obtain, maintain or enforce the patent protection necessary to commercialize products or product candidates developed by them or to competing products. If any of Amgen’s or Novartis’ patents or other intellectual property rights are infringed or misappropriated, or if they are found to be invalid or unenforceable, Amgen or Novartis could lose valuable rights relating to their products. The breadth of issued or allowed patents and the scope of their valid claims are uncertain and subject to challenge by third parties.

References

11. Aimovig Prescribing Information